Capecitabine
Total Neoadjuvant Treatment
Seoul National University HospitalSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Total Neoadjuvant Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin West China Hospital | Phase 3 | B |
ETOPOSIDE West China Hospital | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II West China Hospital | Phase 3 | B |
Toripalimab Ruijin Hospital | Phase 2 | CCC |
FLUOROURACILUM Seoul National University Hospital | N/A | D |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →